Exact Mass: 777.3852929999999

Exact Mass Matches: 777.3852929999999

Found 26 metabolites which its exact mass value is equals to given mass value 777.3852929999999, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

6-(2,2-Diphenylethylamino)-9-[(2r,3r,4s,5s)-5-(Ethylcarbamoyl)-3,4-Dihydroxy-Oxolan-2-Yl]-N-[2-[(1-Pyridin-2-Ylpiperidin-4-Yl)carbamoylamino]ethyl]purine-2-Carboxamide

5-{6-[(2,2-diphenylethyl)amino]-2-[(2-{n-[1-(pyridin-2-yl)piperidin-4-yl]-(C-hydroxycarbonimidoyl)amino}ethyl)carbamoyl]-9H-purin-9-yl}-N-ethyl-3,4-dihydroxyoxolane-2-carboximidate

C40H47N11O6 (777.3710602000001)

fumonisin A1

C37H63NO16 (777.4146638)

22-adenosine monophosphoric ester of 2-deoxyecdysone|22-adenosinemonophosphoric ester of 2-deoxyecdysone

C37H56N5O11P (777.3713756)

6-(2,2-Diphenylethylamino)-9-[(2r,3r,4s,5s)-5-(Ethylcarbamoyl)-3,4-Dihydroxy-Oxolan-2-Yl]-N-[2-[(1-Pyridin-2-Ylpiperidin-4-Yl)carbamoylamino]ethyl]purine-2-Carboxamide

C40H47N11O6 (777.3710602000001)

6-(2,2-Diphenylethylamino)-9-[(2r,3r,4s,5s)-5-(Ethylcarbamoyl)-3,4-Dihydroxy-Oxolan-2-Yl]-N-[2-[(1-Pyridin-2-Ylpiperidin-4-Yl)carbamoylamino]ethyl]purine-2-Carboxamide

5-{6-[(2,2-diphenylethyl)amino]-2-[(2-{n-[1-(pyridin-2-yl)piperidin-4-yl]-(C-hydroxycarbonimidoyl)amino}ethyl)carbamoyl]-9H-purin-9-yl}-N-ethyl-3,4-dihydroxyoxolane-2-carboximidate

C40H47N11O6 (777.3710602000001)

(31R)-8-ethyl-12-methylbacteriochlorophyll d

C48H57MgN4O4- (777.4230081999999)

Grahamine D, (rel)-

C43H59N3O10 (777.4200234000001)

A natural product found in Schizanthus grahamii.

PC 22:6/11:3;O3

C41H64NO11P (777.4216763999999)

PC 33:9;O3

C41H64NO11P (777.4216763999999)

LNAPS 35:8;O

C41H64NO11P (777.4216763999999)

PS 22:5/13:3;O

C41H64NO11P (777.4216763999999)

PS 22:6/12:3;O2

C40H60NO12P (777.3852929999999)

PS 34:9;O2

C40H60NO12P (777.3852929999999)

PS 35:8;O

C41H64NO11P (777.4216763999999)

CYM2503

C45H55N5O7 (777.410128)

CYM2503 is a putative GalR2-positive allosteric modulator. CYM2503 increases the latency to first electrographic seizure and decreases the total time in seizure. CYM2503 also attenuates electroshock-induced seizures in mice. Galanin receptors type 1 (GalR1) and/or type 2 (GalR2) represent unique pharmacological targets for the research of seizures and epilepsy[1].

(4s,10s,13s,16s,19s,22r)-10-[(2s)-butan-2-yl]-3,12,15,18,21,24-hexahydroxy-16-[(1r)-1-hydroxyethyl]-19-[(4-hydroxyphenyl)methyl]-13-methyl-22-(sec-butyl)-2,8,11,14,17,20,23-heptaazatricyclo[23.4.0.0⁴,⁸]nonacosa-1(29),2,11,14,17,20,23,25,27-nonaen-9-one

(4s,10s,13s,16s,19s,22r)-10-[(2s)-butan-2-yl]-3,12,15,18,21,24-hexahydroxy-16-[(1r)-1-hydroxyethyl]-19-[(4-hydroxyphenyl)methyl]-13-methyl-22-(sec-butyl)-2,8,11,14,17,20,23-heptaazatricyclo[23.4.0.0⁴,⁸]nonacosa-1(29),2,11,14,17,20,23,25,27-nonaen-9-one

C40H55N7O9 (777.406106)

11-(4-hydroxyphenyl)-n-[5,8,11,14-tetrahydroxy-6,9-bis(c-hydroxycarbonimidoylmethyl)-3,12-diisopropyl-16-methyl-2-oxo-1-oxa-4,7,10,13-tetraazacyclohexadeca-4,7,10,13-tetraen-15-yl]undeca-2,4,6,8,10-pentaenimidic acid

11-(4-hydroxyphenyl)-n-[5,8,11,14-tetrahydroxy-6,9-bis(c-hydroxycarbonimidoylmethyl)-3,12-diisopropyl-16-methyl-2-oxo-1-oxa-4,7,10,13-tetraazacyclohexadeca-4,7,10,13-tetraen-15-yl]undeca-2,4,6,8,10-pentaenimidic acid

C39H51N7O10 (777.3697226)

(4s,10s,13s,16s,19s,22s)-10,22-bis[(2s)-butan-2-yl]-3,12,15,18,21,24-hexahydroxy-16-[(1r)-1-hydroxyethyl]-19-[(4-hydroxyphenyl)methyl]-13-methyl-2,8,11,14,17,20,23-heptaazatricyclo[23.4.0.0⁴,⁸]nonacosa-1(29),2,11,14,17,20,23,25,27-nonaen-9-one

(4s,10s,13s,16s,19s,22s)-10,22-bis[(2s)-butan-2-yl]-3,12,15,18,21,24-hexahydroxy-16-[(1r)-1-hydroxyethyl]-19-[(4-hydroxyphenyl)methyl]-13-methyl-2,8,11,14,17,20,23-heptaazatricyclo[23.4.0.0⁴,⁸]nonacosa-1(29),2,11,14,17,20,23,25,27-nonaen-9-one

C40H55N7O9 (777.406106)

(2-{3a,7-dihydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-6-hydroxy-6-methylheptan-3-yl)oxy([5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy)phosphinic acid

(2-{3a,7-dihydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-6-hydroxy-6-methylheptan-3-yl)oxy([5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy)phosphinic acid

C37H56N5O11P (777.3713756)

[(2s,3r)-2-[(1r,3as,5ar,7s,9ar,9br,11ar)-3a,7-dihydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-6-methylheptan-3-yl]oxy([(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy)phosphinic acid

[(2s,3r)-2-[(1r,3as,5ar,7s,9ar,9br,11ar)-3a,7-dihydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-6-methylheptan-3-yl]oxy([(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy)phosphinic acid

C37H56N5O11P (777.3713756)

3,12,15,18,21,24-hexahydroxy-16-(1-hydroxyethyl)-19-[(4-hydroxyphenyl)methyl]-13-methyl-10,22-bis(sec-butyl)-2,8,11,14,17,20,23-heptaazatricyclo[23.4.0.0⁴,⁸]nonacosa-1(29),2,11,14,17,20,23,25,27-nonaen-9-one

3,12,15,18,21,24-hexahydroxy-16-(1-hydroxyethyl)-19-[(4-hydroxyphenyl)methyl]-13-methyl-10,22-bis(sec-butyl)-2,8,11,14,17,20,23-heptaazatricyclo[23.4.0.0⁴,⁸]nonacosa-1(29),2,11,14,17,20,23,25,27-nonaen-9-one

C40H55N7O9 (777.406106)

(2e,4e,6e,8e,10e)-11-(4-hydroxyphenyl)-n-[(3s,6s,9s,12s,15s,16r)-5,8,11,14-tetrahydroxy-6,9-bis(c-hydroxycarbonimidoylmethyl)-3,12-diisopropyl-16-methyl-2-oxo-1-oxa-4,7,10,13-tetraazacyclohexadeca-4,7,10,13-tetraen-15-yl]undeca-2,4,6,8,10-pentaenimidic acid

(2e,4e,6e,8e,10e)-11-(4-hydroxyphenyl)-n-[(3s,6s,9s,12s,15s,16r)-5,8,11,14-tetrahydroxy-6,9-bis(c-hydroxycarbonimidoylmethyl)-3,12-diisopropyl-16-methyl-2-oxo-1-oxa-4,7,10,13-tetraazacyclohexadeca-4,7,10,13-tetraen-15-yl]undeca-2,4,6,8,10-pentaenimidic acid

C39H51N7O10 (777.3697226)